Comirnaty
-
Pfizer Shaves Revenue Projections, Starts Cost-Cutting Plan Amid Lower Covid-19 Product Demand
Pfizer lowered its revenue projections for 2023, a change it attributed to declining demand for its Covid-19 vaccine, Comirnaty, and antiviral drug, Paxlovid. Citing this revenue decline, Pfizer is implementing a companywide cost-cutting plan projected to save $3.5 billion.